START Trial Update

This podcast is about a long term follow up to the START trial which originally showed that starting
antiretroviral therapy even at high CD4 counts (above 500) was better than waiting until CD4 counts drop to
<350. It was the impetus to change guidelines to recommend that all patients with HIV be started on
treatment as early as possible. This update was a presentation at ID week late Oct 2022 that showed that the
benefit of early treatment persisted for several years after the original study and that there were still some
differences between the two groups over 6 years after everyone had been placed on treatment. Related Content:

• Babiker AG, Lundgren J, Sharma S, et al. Long term benefits from early antiretroviral therapy initiation in HIV
  infection: findings from the extended follow-up of the START trial. IDWeek 2022, October 19-23, 2022,
  Washington, DC. Abstract LB2305.
• INSIGHT START Study Group :Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl
  J Med. 2015;373:795-807. doi: 10.1056/NEJMoa1506816.
  https://www.nejm.org/doi/10.1056/NEJMoa1506816?url_ver=Z39.88-
  2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov
• IDWeek 2022 Program
• Infectious Disease Society of America (IDSA)
• HIV Guidelines.org
• https://ceitraining.org/request/
• CEI toll free line for NYS providers: 866-637-2342
• https://ceitraining.org/